rs2094258

This document is a comprehensive collection of ~1,200 cancer-related research abstracts and summaries published in various journals (2013), covering clinical trials, pharmacogenomic studies, and mutation analyses across multiple cancer types including colorectal, breast, lung, lymphoma, and other malignancies. The collection documents associations between genetic variants (SNPs and somatic mutations), gene expression patterns, and cancer treatment outcomes, including studies on KRAS, EGFR, TP53, BRAF, and pharmacogenomic variants like CYP3A4 and UGT1A1.

This is a comprehensive journal compilation containing multiple oncology and pharmacogenomics studies published in 2013 across various journals. The collection includes 60+ papers covering cancer treatment outcomes, genetic polymorphisms predicting chemotherapy response and survival, pharmacogenetic variants in drug metabolism and DNA repair genes, and prognostic biomarkers in various cancer types including breast, lung, colorectal, hematologic malignancies, and others. Key findings include associations of XRCC1 variants (rs915927, rs76507, rs2854501, rs2854509, rs3213255) with bladder cancer chemotherapy survival, ABCG2 rs2725264 with lung cancer overall survival (HR 3.22), SLCO1B1 rs4149056 with methotrexate pharmacokinetics, MTHFR rs1801131 with acute lymphoblastic leukemia outcome, and ABCC3/GSTM variants with acute myeloid leukemia survival.

A case-control study of 1,125 gastric cancer cases and 1,196 controls in an Eastern Chinese population examined three polymorphisms in the XPG gene (nucleotide excision repair gene). The XPG rs873601G>A polymorphism was significantly associated with increased gastric cancer risk (adjusted OR = 1.30; 95% CI = 1.03-1.64 for AA vs GG/AG genotypes; p = 0.030), with stronger associations in older age (≥59 years), males, ever-smokers, and non-gastric cardia adenocarcinoma patients. The rs2094258 and rs2296147 SNPs showed no significant associations with risk.